Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
AssigneePureTech LYT, Inc.
InventorsAleksandra FILIPOVIC, Eric ELENKO, Heather PADEN, Christopher KORTH
Life of this patent
Estimating the term…
Abstract
Disclosed herein are combined therapies for treating solid tumors (e.g., pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), cholangiocarcinoma (CAA), renal cell carcinoma (RCC), urothelial, head and neck, breast cancer, lung cancer, or other gastrointestinal solid tumors), comprising an antibody that binds human galectin-9 (anti-Gal9) antibody, e.g., G9.2-17), and one or more chemotherapeutics, for example, gemcitabine, paclitaxel, or a combination thereof.
Claims46
A method for treating a solid tumor, comprising administering to a subject in need thereof an effective amount of an antibody that binds human galectin-9 (anti-Gal9 antibody) and an effective amount of one or more chemotherapeutics;
- wherein the anti-Gal9 antibody has the same heavy chain complementarity determining regions (CDRs) and the same light chain CDRs as antibody G9.2-17, and wherein the subject has one or more of the following features:
- (i) has no resectable cancer;
- (ii) has no infection by SARS-CoV-2;
- and
- (iii) has no active brain or leptomeningeal metastasis.
A method for treating a solid tumor, comprising administering to a subject in need thereof an effective amount of an antibody that binds human galectin-9 (anti-Gal9 antibody) and an effective amount of one or more chemotherapeutics;
- wherein the anti-Gal-9 antibody comprises:
- (a) a light chain comprising a light chain variable region (VL), which comprises a light chain (LC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:
- 1, a LC complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO:
- 2, and a LC complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO:
- 3 and
- (b) a heavy chain comprising a heavy chain variable region (VH), which comprises a heavy chain (HC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:
- 4, a HC complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO:
- 5, and a HC complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO:
- 6;
- and
- wherein the anti-Galectin-9 antibody is administered to the subject at a dose of about 0.2-32 mg/kg once every week, optionally wherein the anti-Galectin-9 antibody is administered to the subject at a dose of about 10 mg/kg to about 16 mg/kg once every week.
Dependencies are inferred from the claim text.